Pharma Journalist 9001 posts 0 comments

Johnson & Johnson has announced plans to invest more than $1 billion in Jacksonville, Florida, to expand its Vision business operations and strengthen domestic manufacturing,…
Read More...

Alkermes plc has received significant regulatory recognition for its investigational sleep disorder therapy alixorexton, with health authorities in both the United States and Europe…
Read More...

Chiesi Group has completed its acquisition of KalVista Pharmaceuticals, marking a significant expansion of its rare diseases business and adding a recently approved hereditary…
Read More...

Johnson & Johnson has reported positive results from the Phase 2/3 ENERGY study evaluating IMAAVY® (nipocalimab-aahu) in patients with warm autoimmune hemolytic anemia (wAIHA), a…
Read More...

GSK has received a significant regulatory boost for its investigational efforts in rare diseases after both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency…
Read More...

Roche has moved a step closer to expanding the use of its immunotherapy Tecentriq® (atezolizumab) in early-stage colon cancer after the U.S. Food and Drug Administration (FDA) accepted…
Read More...

Akeso has secured regulatory approval in China for gumokimab (AK111), its internally developed anti-IL-17 monoclonal antibody, for the treatment of adults with moderate-to-severe plaque…
Read More...

Parabilis Medicines, Inc., a clinical-stage biopharmaceutical company focused on developing therapies against historically difficult-to-target disease-driving proteins, has successfully…
Read More...

XtalPi has entered into a strategic collaboration with a leading international biopharmaceutical company to develop a next-generation small-molecule therapy targeting a complex G…
Read More...

The United Kingdom has become the first country in Europe to approve Wegovy® pill (semaglutide tablets) for weight management, providing adults living with obesity or overweight a new…
Read More...